Here are Morgan Stanley’s key oncology catalysts for 2025
[ad_1]
Here are Morgan Stanley’s key oncology catalysts for 2025
[ad_2]
Similar Posts
REGENXBIO partners with Nippon Shinyaku for MPS therapies
Byadmin
[ad_1] YinYang REGENXBIO (NASDAQ:RGNX) and Nippon Shinyaku have entered into a partnership for the development and commercialization of REGENXBIO’s gene therapies RGX-121 for the treatment of Hunter syndrome, or MPS II, and RGX-111 for Hurler syndrome, or MPS I. Under the deal, REGENXBIO ( [ad_2]
What to watch out for in 2025 (including a rate hike) – Apollo's Slok
Byadmin
[ad_1] What to watch out for in 2025 (including a rate hike) – Apollo's Slok [ad_2]
JPMorgan Diversified Return U.S. Small Cap Equity ETF declares quarterly distribution of $0.2920
Byadmin
[ad_1] JPMorgan Diversified Return U.S. Small Cap Equity ETF declares quarterly distribution of $0.2920 [ad_2]
Nasdaq, Portuguese bank Novobanco expand technology partnership
Byadmin
[ad_1] Nasdaq, Portuguese bank Novobanco expand technology partnership [ad_2]
Bain, KKR bids reach $7.6B billion for Seven & i non-core assets – Reuter
Byadmin
[ad_1] Roman Tiraspolsky/iStock Editorial via Getty Images Private equity firms Bain Capital and KKR & Co. (KKR) each bid more than $5 billion for the non-core assets of 7-Eleven’s parent company Seven & I Holdings Co. (OTCPK:SVNDY). KKR offered around 800B yen ($5.1B), while Bain offered around 1.2T yen ($7.6B) in [ad_2]
Bill Ackman says common stocks of GSEs offer 'large asymmetric upside'
Byadmin
[ad_1] Bill Ackman says common stocks of GSEs offer 'large asymmetric upside' [ad_2]